ClinVar Miner

Submissions for variant NM_000238.4(KCNH2):c.1675C>T (p.Leu559Phe)

dbSNP: rs794728374
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 2
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000181804 SCV000234107 pathogenic not provided 2014-02-05 criteria provided, single submitter clinical testing p.Leu559Phe (CTC>TTC): c.1675 C>T in exon 7 of the KCNH2 gene (NM_000238.2)While the L559F mutation in the KCNH2 gene has not been reported to our knowledge, a mutation affecting this same residue, L559H, has been reported in association with LQTS (Liu et al., 2002). Additionally, mutations in nearby residues (A558E, A558P, A561P, A561T, A561V) have been reported in association with LQTS, further supporting the functional importance of this residue and this region of the protein. L559F results in a conservative amino acid substitution as these residues share similar properties, and are least likely to impact secondary structure. The L559F residue is completely conserved across species and in silico analysis predicts L559F is damaging to the protein structure/function. Furthermore, L559F was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations.In summary, L559F in the KCNH2 gene is interpreted as a likely disease-causing mutation. The variant is found in LQT panel(s).
Ambry Genetics RCV002399646 SCV002714392 uncertain significance Cardiovascular phenotype 2020-12-08 criteria provided, single submitter clinical testing The p.L559F variant (also known as c.1675C>T), located in coding exon 7 of the KCNH2 gene, results from a C to T substitution at nucleotide position 1675. The leucine at codon 559 is replaced by phenylalanine, an amino acid with highly similar properties, and is located in the S5 domain. This alteration has been reported in a long QT syndrome (LQTS) cohort (Itoh H et al. Eur Heart J, 2016 May;37:1456-64). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.